검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Product (Anti-Tumor Necrosis Factor Alpha Drug, Anti-Tumor Necrosis Factor Alpha Drug (Product)) R.Bos·Rheumatoid Arthritis ORR 1.8% |
|---|---|
Overview Program | Anti-Tumor Necrosis Factor Alpha Drug (Product) |
Overview Company | R.Bos |
Overview Modality | ANTIBODY |
Overview Target | Rheumatoid Arthritis |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | target toxicity, as further supported by transcriptomic analysis revealing downregulation of fibrosis- and metabolism-related pathway |
MoA Biomarker | biomarkers, and well-designed clinical trials with vascular or cardiovascular endpoints are required before c |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Hypersensitivity reactions associated with nutraceuticals and dietary supplements: A narrative review.. The global use of nutraceuticals and dietary supplements-including vitamins, minerals, probiotics, and botanical extracts-has increased substantially, driven largely by consumer perceptions of safety and health benefits. However, their potential to cause hypersensitivity reactions (HSRs) is unde… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 1.8% |
Clinical ORR | 1.80% |
Clinical Result source | ClinicalTrials.gov NCT00124982 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Product (Anti-Tumor Necrosis Factor Alpha Drug, Anti-Tumor Necrosis Factor Alpha Drug (Product)) R.Bos·Rheumatoid Arthritis ORR 1.8% |
|---|---|
Overview Program | Anti-Tumor Necrosis Factor Alpha Drug (Product) |
Overview Company | R.Bos |
Overview Modality | ANTIBODY |
Overview Target | Rheumatoid Arthritis |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | target toxicity, as further supported by transcriptomic analysis revealing downregulation of fibrosis- and metabolism-related pathway |
MoA Biomarker | biomarkers, and well-designed clinical trials with vascular or cardiovascular endpoints are required before c |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Hypersensitivity reactions associated with nutraceuticals and dietary supplements: A narrative review.. The global use of nutraceuticals and dietary supplements-including vitamins, minerals, probiotics, and botanical extracts-has increased substantially, driven largely by consumer perceptions of safety and health benefits. However, their potential to cause hypersensitivity reactions (HSRs) is unde… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 1.8% |
Clinical ORR | 1.80% |
Clinical Result source | ClinicalTrials.gov NCT00124982 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교